Corvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Get Rating) in a research report report published on Thursday morning. The firm issued a hold rating on the stock. CRVS has been the subject of several other research reports. Cantor Fitzgerald raised their price target on Corvus Pharmaceuticals from $2.00 to $4.00 in a […]

Related Keywords

,Institutional Trading Of Corvus Pharmaceuticals ,News Ratings For Corvus Pharmaceuticals Daily ,Discovery Capital Management ,Corvus Pharmaceuticals ,Corvus Pharmaceuticals Trading ,Renaissance Technologies ,Corvus Pharmaceuticals Inc ,Cantor Fitzgerald ,Nasdaq ,Corvus Pharmaceuticals Company Profile ,Get Rating ,Capital Management ,Sigma Advisers ,Sigma Investments ,Adenosine Production Inhibitor ,Corvus Pharmaceuticals Daily ,Nasdaq Crvs ,Ccrvs ,Medical ,Initiated Coverage ,Stocknews Com ,